Yanhao is my first graduate student. Today he passed oral comprehensive exam. This is a big milestone for him! I am so proud for how much he has accomplished so far. Congrats, Yanhao!
He also won the “outstanding research award” recently. The future is bright for him

Do you have #Lynchsyndrome ? See if you qualify to participate in a clinical trial

bit.ly/ihavelynch

#cancerprevention UAZCancer Community Outreach & Engagement Aaron J. Scott MD National Cancer Institute Lynch Syndrome Intl

👏 👏 Aaron J. Scott MD for great job championing NRG Oncology GI005 COBRA trial evaluating ctDNA as predictive marker for adj chemo in stage II colon cancer at SWOG Cancer Research Network-we recognize power of liquid biopsy & need definitive prospective data for acting on results! Trial open across US & Canada

Do you have #Lynchsyndrome ? See if you qualify to participate in a clinical trial bit.ly/ihavelynch #cancerprevention UAZCancer Community Outreach & Engagement Aaron J. Scott MD National Cancer Institute Lynch Syndrome Intl

University of Arizona Cancer Center Community Outreach and Engagement and Office of Diversity, Equity and Inclusion is strongly represented at #AACR23 to take part in the discussion of Hispanic health disparities. #CancerResearch #UACCCOE

Dr. Sharad Khurana, a hematologist at Banner – University Medicine and a member of the UArizona Cancer Center, was interviewed by KGUN 9 for a story on the importance of bone marrow registration. You can read and watch the KGUN9 interview here: bit.ly/3lYm7uB

In honor of Women's History Month, and women currently making history: We're not sure how UACC Associate Director of Clinical Investigations, Rachna Shroff, gets it all done, but we're honored to have her help lead our team. Read a feature about her here: tinyurl.com/yckvmkcr

Very excited to see the NRG Oncology GI005 study team at ASCO #GI23 - this ph 2/3 trial evaluating #ctDNA as a biomarker for adj chemo benefit in pts w/ low risk stage 2a colon cancer continues to enroll well in US and Canada! SWOG Cancer Research Network ECOG-ACRIN Cancer Research Group Alliance for Clinical Trials in Oncology

The Natera GALAXY trial in Nature Medicine:
Molecular residual disease (measured by tumor informed ctDNA) & efficacy of adjuvant chemotherapy in patients with #ColorectalCancer . At 4w post survey, ctDNA+ is associated with recurrence.
#OpenAccess
nature.com/articles/s4159…

An UAZ Engineering, University of Arizona Cancer Center, BIO5 Institute project, with funding from the state's #NewEconomyInitiative , creates humanlike cancer models and growth environments to help improve prevention, diagnosis and treatment. bit.ly/3FAjMMr

With colorectal liver metastases remaining a leading cause of mortality for patients with cancer, should adjuvant/perioperative chemo be reevaluated as a standard of care? Dr. Cathy Eng & Sepideh Gholami, MD, MAS, FACS, FSSO discuss. fal.cn/3uoJo #gicsm #crcsm #ASCODailyNews

For #ASCODailyNews , Junaid Arshad, Umbreen Rozell, and Aaron J. Scott MD of University of Arizona Cancer Center discuss the advantages of attending the upcoming #GI23 for trainees/junior faculty and community oncologists: fal.cn/3tuyD #OncTwitter #MedTwitter #gicsm

Not an amazing score, but happy with it after 4 subs/2 study sections in 2 years in NCI. Thanks to collaborators Aaron J. Scott MD, Michael Kuhns, trainees. We are hiring postdoc/PhD students. UArizona R. Ken Coit College of Pharmacy University of Arizona Research University of Arizona Cancer Center BIO5 Institute PhRMA Foundation NIGMS UA SWEHSC National Cancer Institute

A celebration for the books! University of Arizona Cancer Center celebrated its CCSG renewal today with the support of Robert C. Robbins University of Arizona Health Sciences’s Dr. Dake and UArizona SVPRI! Joann Sweasy University of Arizona Cancer Center_COE BIO5 Institute University of Arizona COM - Division of Heme/Onc

The biology of BRAF mCRC tumors are not uniform
Study of RNA profiles has separated it into 2 groups
1. BRAF Mutation 1 (BM1): ⬆️ MAPK signature,⬆️ PI3K/mTOR pathway signature

2. BRAF Mutation 2 ( BM2) - ⬆️ cell cycle signature
BM2 also has⬆️ MSI-H pts
#CRCTrialsChat